Sigrid Therapeutics Receives Notice of Allowance for US Patent Covering Novel Porous Silica Materials
Stockholm, Sweden – September 8, 2025 – Sigrid Therapeutics is pleased to announce that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for its patent application US2022135411A1, titled “Highly Structured Porous Silica Materials and Biological Uses Thereof”. This achievement marks a key milestone in the company’s intellectual property strategy and underscores its leadership in advancing next-generation silica-based health technologies.
The patent application covers novel porous silica particles featuring a unique hierarchical pore structure, which relates to Sigrid’s proprietary technology platform SiPore®. Unlike conventional silica, SiPore® is engineered with precisely controlled pores that can entrap digestive enzymes in the gut. By harnessing this physical mechanism, SiPore® opens new possibilities for clinically proven, non-systemic solutions in areas such as blood sugar regulation, weight management, and broader metabolic health.
“This milestone validates the strength of our scientific innovation and the uniqueness of our technology,” said Ghislaine Robert-Nicoud, Head of Product Development at Sigrid Therapeutics. “With the US being a key market, this patent strengthens our commercial position and ability to delivery novel solutions that address some of the most pressing health challenges of our time.”
The patent is expected to be formally granted following completion of administrative procedures and will further strengthen Sigrid’s expanding portfolio of granted patents. In the United States, the company already holds US 10,695,294 and US 12,121,612. In Europe, Sigrid Therapeutics holds EP2916852B1, validated across major markets including the EU, UK, Switzerland, Norway, Iceland, and Turkey. The company also holds granted patents in Canada, Australia, Japan, and Israel.
About Sigrid Therapeutics
Sigrid Therapeutics is a Swedish innovative consumer care company redefining metabolic health with its patented SiPore® technology. Backed by over 15 years of research, SiPore® is a 100% natural mineral that works locally in the gut — mechanically capturing digestive enzymes to slow carbohydrate and fat breakdown, reducing calorie absorption without affecting essential micronutrients. This purely local, non-systemic mode of action is designed to help manage blood sugar levels, supports healthy weight management, and promotes overall metabolic health— all without entering the bloodstream or causing systemic side effects.
The SiPore® portfolio includes:
Carb Fence™ – a fast-acting, medical food formulated for the dietary management of impaired glucose tolerance and related metabolic conditions, to be used under medical supervision.
Glucose Stabiliser – a daily dietary supplement for health-conscious consumers seeking long-term metabolic balance.